Therapeutic Asset Ratings

164 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Pooled Mutant Kras-Targeted Long Peptide Vaccine 0. Each; 1. Total Peptides Non-Small Cell Lung Carcinoma	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	P1	C (36)
pt0511 Non-Small Cell Lung Carcinoma	PAQ Therapeutics, Inc.	P1	C (36)
Sdt-M001 Non-Small Cell Lung Carcinoma	Cytocraft Biopharmaceutical Co., Ltd.	P1	C (36)
sim0610 for Non-Small Cell Lung Carcinoma	Jiangsu Simcere Pharmaceutical Co., Ltd.	P1	C (36)
tas3351 Non-Small Cell Lung Carcinoma	Taiho Oncology, Inc.	P1	C (36)
Tbio-4101 Non-Small Cell Lung Carcinoma	Turnstone Biologics, Corp.	P1	C (36)
tcr1188-abc cells Non-Small Cell Lung Carcinoma	University of Pennsylvania	P1	C (36)
TIPIRACIL Non-Small Cell Lung Carcinoma	AbbVie	P1	C (36)
Trifluridine Non-Small Cell Lung Carcinoma	AbbVie	P1	C (36)
VASCULAR ENDOTHELIAL GROWTH FACTOR A Non-Small Cell Lung Carcinoma	BioNTech SE	P1	C (36)
Tarloxotinib Non-Small Cell Lung Carcinoma	Medical University of South Carolina	P2	D (30)
Tisagenlecleucel Non-Small Cell Lung Cancer	National Cancer Institute (NCI)		D (26)
rx001 Non-Small Cell Lung Carcinoma	GeneCraft Inc.	P1	NR (0)
Xingbaiji Formula Non-Small Cell Lung Carcinoma	Jiangxi Provincial People's Hopital	N/A	NR (0)

Showing 151 to 164 of 164 assets

PreviousPage 7 of 7Next